Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and Fatty Liver

sorafenib has been researched along with Fatty Liver in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Calvisi, DF; Chen, X; Evert, M; O'Farrell, M; Roessler, S; Shang, R; Stahl, A; Sticht, C; Wang, H; Wang, X; Xu, H; Zeng, Y; Zhang, Y; Zhou, Y1
Inayat, F; Lodhi, HT; Ullah, W; Zafar, F1
Hsieh, YC; Huang, YT; Lee, FY; Lee, KC; Lee, PC; Lee, WP; Lin, HC; Liu, RS; Tan, TW; Yang, YY; Yeh, YC1
Chan, CC; Huang, YT; Lee, KC; Lee, TY; Lin, HC; Yang, YY; Yeh, YC1

Other Studies

4 other study(ies) available for sorafenib and Fatty Liver

ArticleYear
Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
    Hepatology (Baltimore, Md.), 2022, Volume: 76, Issue:4

    Topics: Anilides; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Fatty Acid Synthase, Type I; Fatty Acid Synthases; Fatty Liver; Humans; Liver; Liver Neoplasms; Mammals; Mice; Phosphoric Monoester Hydrolases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Pyridines; Sorafenib; Tensins; TOR Serine-Threonine Kinases

2022
Primary peritoneal hepatoid adenocarcinoma: a diagnostic and therapeutic conundrum in patients with gastrointestinal bleeding.
    BMJ case reports, 2018, Sep-18, Volume: 2018

    Topics: Adenocarcinoma; Anemia, Iron-Deficiency; Antineoplastic Agents; Carcinoma, Hepatocellular; Docetaxel; Fatty Liver; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Palliative Care; Peritoneal Neoplasms; Sorafenib

2018
Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:4

    Topics: Alanine; Animals; Ascites; Cytokines; DNA Primers; Fatty Liver; Fibroblast Growth Factors; Microcirculation; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Platelet-Derived Growth Factor; Positron-Emission Tomography; Rats; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Splanchnic Circulation; Triazines; Vascular Endothelial Growth Factor A

2014
Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2012, Volume: 18, Issue:11

    Topics: Animals; Apoptosis; Disease Models, Animal; Fatty Liver; Gene Expression Regulation, Enzymologic; Hemodynamics; Inflammation; Liver; Male; MAP Kinase Signaling System; Necrosis; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Reperfusion Injury; rho-Associated Kinases; RNA, Messenger; Sorafenib; Transplantation, Homologous

2012